公开(公告)号：DE3886118D1

公开(公告)日：1994-01-20

申请号：DE3886118

申请日：1988-07-13

Applicant: SCLAVO SPA

Inventor： PROTASI OTELLO ,  RAPPUOLI PAOLO

IPC: A61K38/00 ,  C07K14/565 ,  C12P21/02 ,  C07K3/20 ,  A61K37/66

Abstract: A method is described for the purification of crude human interferon from solutions containing it, which comprises: a) the complete adsorption of the crude interferon in a column of siliceous material which has previously been disinfected with an aqueous solution of formaldehyde; b) the washing of the column with non-pyrogenic, sterile, deionised water; c) the removal of the extraneous residual proteins by the elution of the column successively with a 1.4 M aqueous solution of NaCl, with non-pyrogenic, sterile, deionised water, and with an aqueous solution of a solvent having hydrophobic and acidic properties at a molar concentration of 0.001 M to 0.003 M; d) the elution of the interferon from the column with an aqueous solution of the same solvent as that used in step c) at a molar concentration of from 0.01 to 0.03 M and finally, e) the recovery and lyophilisation of the eluted fraction and/or fractions containing the purified interferon. The method enables interferon to be obtained, the purity of which, measured as its specific activity, is at least 1000 times greater than that of the crude interferon, with a yield greater than 85%. The interferon thus purified is particularly useful for treatment in man.

公开(公告)号：IT1222427B

公开(公告)日：1990-09-05

申请号：IT2156087

申请日：1987-07-31

Applicant: SCLAVO SPA

Inventor： PROTASI OTELLO ,  RAPPUOLI PAOLO

IPC: A61K38/00 ,  C07K14/565 ,  C12P21/02 ,  A61K

Abstract: A method is described for the purification of crude human interferon from solutions containing it, which comprises: a) the complete adsorption of the crude interferon in a column of siliceous material which has previously been disinfected with an aqueous solution of formaldehyde; b) the washing of the column with non-pyrogenic, sterile, deionised water; c) the removal of the extraneous residual proteins by the elution of the column successively with a 1.4 M aqueous solution of NaCl, with non-pyrogenic, sterile, deionised water, and with an aqueous solution of a solvent having hydrophobic and acidic properties at a molar concentration of 0.001 M to 0.003 M; d) the elution of the interferon from the column with an aqueous solution of the same solvent as that used in step c) at a molar concentration of from 0.01 to 0.03 M and finally, e) the recovery and lyophilisation of the eluted fraction and/or fractions containing the purified interferon. The method enables interferon to be obtained, the purity of which, measured as its specific activity, is at least 1000 times greater than that of the crude interferon, with a yield greater than 85%. The interferon thus purified is particularly useful for treatment in man.

公开(公告)号：IT8721560D0

公开(公告)日：1987-07-31

申请号：IT2156087

申请日：1987-07-31

Applicant: SCLAVO SPA

Inventor： RAPPUOLI PAOLO ,  PROTASI OTELLO

IPC: A61K38/00 ,  C07K14/565 ,  C12P21/02

Abstract: A method is described for the purification of crude human interferon from solutions containing it, which comprises: a) the complete adsorption of the crude interferon in a column of siliceous material which has previously been disinfected with an aqueous solution of formaldehyde; b) the washing of the column with non-pyrogenic, sterile, deionised water; c) the removal of the extraneous residual proteins by the elution of the column successively with a 1.4 M aqueous solution of NaCl, with non-pyrogenic, sterile, deionised water, and with an aqueous solution of a solvent having hydrophobic and acidic properties at a molar concentration of 0.001 M to 0.003 M; d) the elution of the interferon from the column with an aqueous solution of the same solvent as that used in step c) at a molar concentration of from 0.01 to 0.03 M and finally, e) the recovery and lyophilisation of the eluted fraction and/or fractions containing the purified interferon. The method enables interferon to be obtained, the purity of which, measured as its specific activity, is at least 1000 times greater than that of the crude interferon, with a yield greater than 85%. The interferon thus purified is particularly useful for treatment in man.

公开(公告)号：AT133421T

公开(公告)日：1996-02-15

申请号：AT91103719

申请日：1991-03-12

Applicant: SCLAVO SPA

Inventor： PROTASI OTELLO ,  RAPPUOLI PAOLO

IPC: A61K38/21 ,  A61P35/00 ,  C07K14/565 ,  C12P21/02 ,  C12R1/91 ,  C07K1/00

Abstract: A process for the chromatographic purification of recombinant human beta -interferon wherein: a) an aqueous solution of recombinant human beta -interferon in unrefined state is contacted with a siliceous solid matrix equilibrated with deionized water and then eluted with appropriated eluant; b) the eluted fractions containing the recombinant human beta -interferon purified according to the stage a) are loaded on a cation exchange resin; thereafter the rhu- beta -interferon adsorbed upon said matrix is eluted with an appropriated eluant. The recombinant human beta -interferon purified in this way is specifically useful as active agent in the production of pharmaceutic preparations suitable for the treatment of viral infections, tumors and as immunomodulators.

公开(公告)号：IT1243419B

公开(公告)日：1994-06-10

申请号：IT2156590

申请日：1990-09-25

Applicant: SCLAVO SPA

Inventor： SCAPOL LUCIA ,  PESSI ANTONELLO ,  RAPPUOLI PAOLO ,  VISCOMI GIUSEPPE CLAUDIO

IPC: A61K20060101 ,  C07C20060101 ,  A61K ,  C07C

Abstract: Antiparallel oligopeptides, the sequences of which are suitably defined so that they have affinity for β- interferon, and a process for the purification of human β-interferon using stationary phases consisting of inert matrices onto which the said antiparallel peptides are chemically bound, are described.

公开(公告)号：IT9021564A1

公开(公告)日：1992-03-26

申请号：IT2156490

申请日：1990-09-25

Applicant: SCLAVO SPA

Inventor： RAPPUOLI PAOLO ,  VISCOMI GIUSEPPE CLAUDIO

IPC: A61K20060101

公开(公告)号：IT9019699D0

公开(公告)日：1990-03-16

申请号：IT1969990

申请日：1990-03-16

Applicant: SCLAVO SPA

Inventor： PROTASI OTELLO ,  RAPPUOLI PAOLO

IPC: A61K38/21 ,  A61P35/00 ,  C07K14/565 ,  C12P21/02 ,  C12R1/91

Abstract: A process for the chromatographic purification of recombinant human beta -interferon wherein: a) an aqueous solution of recombinant human beta -interferon in unrefined state is contacted with a siliceous solid matrix equilibrated with deionized water and then eluted with appropriated eluant; b) the eluted fractions containing the recombinant human beta -interferon purified according to the stage a) are loaded on a cation exchange resin; thereafter the rhu- beta -interferon adsorbed upon said matrix is eluted with an appropriated eluant. The recombinant human beta -interferon purified in this way is specifically useful as active agent in the production of pharmaceutic preparations suitable for the treatment of viral infections, tumors and as immunomodulators.

公开(公告)号：DE69116582D1

公开(公告)日：1996-03-07

申请号：DE69116582

申请日：1991-03-12

Applicant: SCLAVO SPA

Inventor： PROTASI OTELLO ,  RAPPUOLI PAOLO

IPC: A61K38/21 ,  A61P35/00 ,  C07K14/565 ,  C12P21/02 ,  C12R1/91 ,  C07K1/00

Abstract: A process for the chromatographic purification of recombinant human beta -interferon wherein: a) an aqueous solution of recombinant human beta -interferon in unrefined state is contacted with a siliceous solid matrix equilibrated with deionized water and then eluted with appropriated eluant; b) the eluted fractions containing the recombinant human beta -interferon purified according to the stage a) are loaded on a cation exchange resin; thereafter the rhu- beta -interferon adsorbed upon said matrix is eluted with an appropriated eluant. The recombinant human beta -interferon purified in this way is specifically useful as active agent in the production of pharmaceutic preparations suitable for the treatment of viral infections, tumors and as immunomodulators.

公开(公告)号：DE3886118T2

公开(公告)日：1994-04-07

申请号：DE3886118

申请日：1988-07-13

Applicant: SCLAVO SPA

Inventor： PROTASI OTELLO ,  RAPPUOLI PAOLO

IPC: A61K38/00 ,  C07K14/565 ,  C12P21/02 ,  C07K3/20 ,  A61K37/66

Abstract: A method is described for the purification of crude human interferon from solutions containing it, which comprises: a) the complete adsorption of the crude interferon in a column of siliceous material which has previously been disinfected with an aqueous solution of formaldehyde; b) the washing of the column with non-pyrogenic, sterile, deionised water; c) the removal of the extraneous residual proteins by the elution of the column successively with a 1.4 M aqueous solution of NaCl, with non-pyrogenic, sterile, deionised water, and with an aqueous solution of a solvent having hydrophobic and acidic properties at a molar concentration of 0.001 M to 0.003 M; d) the elution of the interferon from the column with an aqueous solution of the same solvent as that used in step c) at a molar concentration of from 0.01 to 0.03 M and finally, e) the recovery and lyophilisation of the eluted fraction and/or fractions containing the purified interferon. The method enables interferon to be obtained, the purity of which, measured as its specific activity, is at least 1000 times greater than that of the crude interferon, with a yield greater than 85%. The interferon thus purified is particularly useful for treatment in man.

公开(公告)号：AT98257T

公开(公告)日：1993-12-15

申请号：AT88111201

申请日：1988-07-13

Applicant: SCLAVO SPA

Inventor： PROTASI OTELLO ,  RAPPUOLI PAOLO

IPC: A61K38/00 ,  C07K14/565 ,  C12P21/02 ,  C07K3/20 ,  A61K37/66

Abstract: A method is described for the purification of crude human interferon from solutions containing it, which comprises: a) the complete adsorption of the crude interferon in a column of siliceous material which has previously been disinfected with an aqueous solution of formaldehyde; b) the washing of the column with non-pyrogenic, sterile, deionised water; c) the removal of the extraneous residual proteins by the elution of the column successively with a 1.4 M aqueous solution of NaCl, with non-pyrogenic, sterile, deionised water, and with an aqueous solution of a solvent having hydrophobic and acidic properties at a molar concentration of 0.001 M to 0.003 M; d) the elution of the interferon from the column with an aqueous solution of the same solvent as that used in step c) at a molar concentration of from 0.01 to 0.03 M and finally, e) the recovery and lyophilisation of the eluted fraction and/or fractions containing the purified interferon. The method enables interferon to be obtained, the purity of which, measured as its specific activity, is at least 1000 times greater than that of the crude interferon, with a yield greater than 85%. The interferon thus purified is particularly useful for treatment in man.